Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on November 13, 2017. The filing reports the appointment of Michael Rogers as Chief Financial Officer, effective November 15, 2017, succeeding James Murphy as Interim CFO. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $375,000 annually.
- Performance Bonus: Targeted at 40% of base salary.
- Equity Grant: Stock option to purchase shares equal to 1% of the Company's outstanding capital stock on a fully-diluted basis.
- Vesting Schedule: 25% on the first anniversary of employment, with the remainder vesting monthly thereafter at 2.0833% per month.
Material Changes
The primary material change is the leadership transition in the finance function. Michael Rogers replaces James Murphy as CFO. Rogers brings prior experience as CFO at Acorda Therapeutics (2013-2016), BG Medicine (2009-2012), and Indevus Pharmaceuticals (1999-2009).
Outlook, Risks, and Contingencies
Severance Provisions:
- Standard Termination: If terminated without cause or for good reason, Rogers is entitled to 12 months of base salary, 12 months of medical/dental benefits, and acceleration of vesting for options that would have vested over the next 12 months.
- Change in Control: If termination occurs within 15 months of a change in control, severance increases to 1x the sum of base salary plus target bonus, plus 12 months of benefits and full acceleration of vesting.
Legal Contingencies: The Company entered into a standard indemnification agreement, potentially requiring the Company to cover legal expenses, judgments, fines, and settlements incurred by Rogers arising from his service as an officer. A confidentiality and IP assignment agreement includes non-competition and non-solicitation provisions effective during employment and for one year thereafter.
Investor Verification Checklist
- Verify the exact number of shares underlying the 1% stock option grant based on the fully-diluted capitalization on the grant date.
- Confirm the closing price of the Company's common stock on the OTCQB on the grant date to determine the exercise price.
- Review the definition of "Change in Control" within the employment agreement to assess potential future liability triggers.
- Check subsequent filings for the Board's final approval of the stock option grant as required by the agreement.